A dynamic ecosystem nurturing biotech growth
At Genopole, cooperation isn't just a word, it's a work method, a lever for innovation and a motor for growth. Throughout the year and thanks to the concerted actions of GIP and SEM Genopole, the biocluster demonstrated the strength of connections: those made between labs and start-ups, between entrepreneurs and institutional partners, between start-ups and industrial partners.
Close to 80 biotech businesses and 16 academic labs share the Genopole biocluster. Synergies emerge there where competencies meet, in both the health and bioeconomy sectors. In this setting, investors take the time to analyze projects with rigor and discernment. Sometimes they request more time to make their decisions, but in so doing, further strengthen the solidity and pertinence of the commitments to come.
In 2024, Genopole reinforced its role as a catalyst for innovation within its ecosystem. At the biocluster, businesses and laboratories collaborate, advance and develop together in a synergy-nurturing environment. Year 2024 saw an increase in the number of accompanied businesses, with a particularly strong dynamic in the bioeconomy sector, which illustrates its increasing momentum. The biocluster reached a significant mile-marker, as it now counts ten businesses with sales exceeding €4 million.
Genopole acts side-by-side with entrepreneurs to support project development, strengthen structuration, ease access to funding, and create conditions to favor business establishment in the territory.
Nonetheless, 67% of the biocluster's companies have less than ten employees. That reality make hands-on accompaniment all the more essential. Genopole acts concretely and side-by-side with entrepreneurs to support project development, strengthen structuration, ease access to funding, and create conditions to favor business establishment in the territory. And the results are there: 12 companies enlarged their premises this year, proof of their growth and fidelity to the biocluster. Many companies laid their business paths at Genopole, such as Abolis, Enalees, DNTech and STH Biotech.
The ecosystem remains healthy, nourished by the emergence of new potentialities. Among 2024's successes are the progression of Abolis, the notable fund raising campaigns of STH Biotech and AuraLIP (who met their investors thanks to Genopole) or the creation of ChromoDiag, a spin-off resulting from Genopole's programs.
In an era where biotechnologies are becoming strategic elements of industrial and health sovereignty, Genopole, more than ever, is positioning itself as a catalyst for alliances, a biocluster able to focus efforts on today's and tomorrow's scientific and societal challenges.